TOUCH, The Black Breast Cancer Alliance (TOUCHBBCA)?in collaboration with the Triple Negative Breast Cancer Foundation, the American Association for Cancer Research (AACR), and Nueva Vida?has launched ...
Ideaya Biosciences has made a key hire in anticipation of the launch of its first drug, securing the services of an executive ...
November 19, 2024--(BUSINESS WIRE)--Frazier Life Sciences (FLS), a longstanding investment firm ... Smither served as the ...
Interim results from the ongoing GLISTEN trial of linerixibat, GSK's targeted inhibitor of the ileal bile acid transporter ...
Check the time stamp on this data. Updated AI-Generated Signals for Gilead Sciences Inc. (GILD) available here: GILD.
Try Now>> See today’s best-performing stocks on TipRanks >> Read More on GILD: Gilead Sciences NewsMORE Related Stocks Indices Commodities Currencies Stocks ...
With FDA approval in the bag for its AI-based aortic stenosis diagnostic tool, Echo IQ is focused on commercialisation over the coming years.
Positive Phase 1a interim data released for ABI-5366, a long-acting HSV helicase-primase inhibitor candidate for recurrent genital herpes, supporting potential for once-weekly and once-monthly oral ...
On Friday, Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $88.4 which represents a decrease of $-3.71 or -4.03% from the prior close of $92.11. The stock opened at $91.71 and ...
An update from the PURPOSE 2 trial focused on adherence and pharmacokinetics data for lenacapavir, used to prevent HIV.
RBC Capital analyst Brian Abrahams maintained a Hold rating on Gilead Sciences (GILD – Research Report) today and set a price target of $84.00.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback